HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis.
暂无分享,去创建一个
G La Torre | G. La Torre | A. Mannocci | C. de Waure | W. Ricciardi | G. Chiaradia | W Ricciardi | C de Waure | G Chiaradia | A Mannocci
[1] S. Franceschi,et al. Prevalence of human papillomavirus infection in women in Turin, Italy. , 2005, European journal of cancer.
[2] M. Lehtinen,et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. , 2007, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[3] J M Garden,et al. Papillomavirus in the vapor of carbon dioxide laser-treated verrucae. , 1988, JAMA.
[4] Eduardo Lazcano-Ponce,et al. Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents: A Randomized Controlled Trial , 2007, The Pediatric infectious disease journal.
[5] D. Merlo,et al. Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population , 2005, BMC infectious diseases.
[6] G. Nuovo,et al. Human papillomavirus type 16 DNA in periungual squamous cell carcinomas. , 1989, JAMA.
[7] J. Doorbar,et al. Human Papillomaviruses , 2006, Methods in Molecular Medicine.
[8] C. Wheeler,et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts , 1995, Journal of clinical microbiology.
[9] G. Krogh,et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.
[10] J. Baseman,et al. The epidemiology of human papillomavirus infections. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[11] S. Franceschi,et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis , 2005, The Lancet.
[12] J. Cuzick,et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.
[13] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[14] C. Wheeler,et al. A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.
[15] K. Ault. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review. , 2006, Obstetrical & gynecological survey.
[16] H. Kashima,et al. A comparison of risk factors in juvenile‐onset and adult‐onset recurrent respiratory papillomatosis , 1992, The Laryngoscope.
[17] C. Wheeler,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial , 2005 .
[18] C. Wheeler,et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.
[19] Henry C Kitchener,et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.
[20] C. Wheeler,et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. , 2004, Vaccine.
[21] J. Walboomers,et al. Human papillomavirus and cutaneous warts in meat handlers , 1993, Journal of clinical microbiology.
[22] Cosette M Wheeler,et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.
[23] Daron G Ferris,et al. Efficacy of a bivalent L 1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial , 2005 .
[24] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[25] C. Wheeler,et al. Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.
[26] C. Wheeler,et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. , 2006, Vaccine.
[27] L. Markowitz,et al. Genital human papillomavirus infection. , 2006, The New Zealand medical journal.
[28] Daron G Ferris,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.
[29] K. Holmes,et al. Epidemiology of genital human papillomavirus infection. , 1988, Epidemiologic reviews.
[30] A. Cicchetti,et al. Health Technology Assessment and vaccine: new needs and opportunities? , 2007 .
[31] M. Schiffman,et al. Human Papillomavirus Epidemiology and Public Health , 2022 .